News and Updates

Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)

Abstract: Predictive biomarkers of response to HER2–directed therapy are essential to inform treatment decisions. A previous trial reported that early declines in tumor SUVs corrected for lean body mass (SULmax) on 18F-FDG PET/CT predicted a pathologic complete response to HER2 therapy with neoadjuvant trastuzumab and pertuzumab without chemotherapy in ER–negative, HER2-positive breast cancer. We hypothesized that 18F-FDG PET/CT SULmax parameters would predict recurrence-free survival and overall survival.

Biotech firm nearing completion of Indy radioisotopes factory

Thw San Diego-based biotech firm that is building a plant in Indianapolis to manufacture radioisotopes says it expects the facility to be completed by the end of the year, with production starting next year.  RayzeBio Inc. made the announcement when it filed an amended registration statement to go public. The company had its initial public offering on Friday, September 15th when it priced its stock at $18 a share.

Israeli cancer-fighting science firm plans HQ in Westfield [Indiana]

Isotopia Molecular Imaging, an Israeli nuclear medicine manufacturer, plans to build a $20 million facility and plans on hiring 50 technical, engineering, quality and scientific workers by 2027.

© 2023 Science and Medicine Group

PSMA uptake, access appear high for US-based urologists

"There’s probably some confusion about what some of the providers are ordering because when we looked at other things they were ordering, some of them just named the university they might be ordering from and things like that. So they may not actually know whether they’re using gallium or F 18.” -Urology Times Co–Editor in Chief Michael S. Cookson, MD, MMHC, FACS, who developed the survey

A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes

This review summarizes the development of the actinium-225 labeled compounds and biomolecules.

AUTHOR: Maria Hassan, Tanveer Hussain Bokhari, Nadeem Ahmed Lodhi, Muhammad Kaleem Khosa, Muhammad Usman

SOURCE: Chemical Biology & Drug Design, 00, 1–17.

Copyright © 1999-2023 John Wiley & Sons, Inc.

Initial funding in place for Pallas construction

The Pallas research reactor is to be built at Petten to replace the existing High Flux Reactor (HFR). The 45 MW HFR started operating in September 1960. Pallas will be of the "tank-in-pool" type, with a thermal power of around 55 MW, and able to deploy its neutron flux more efficiently and effectively than the HFR. The new reactor is expected to begin operation around 2024.

Incidental Uptake in a Subacute Stroke on 18F-Piflufolastat PSMA PET/CT

A case of an elderly man who underwent imaging with PSMA PET/CT, which demonstrated uptake in the left parietal-temporal junction that was shown to be a subacute stroke.

AUTHOR: Lewis, Miles C.; Wale, Daniel J.; Liao, Eric; Viglianti, Benjamin

Study: PET/CT Multivariate Model Enhances Accuracy for Diagnosing Prostate Cancer

For men with total PSA scores between 4 to 10 ng/mL, a multivariate prediction model that incorporates 68Ga-PSMA PET/CT had a 92.7 AUC for predicting clinically significant prostate cancer.

© 2023 MJH Life Sciences

Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir: A Pilot PET/CT Study

From Harvard Medical School, 124I-evuzamitide is a novel pan-amyloid radiotracer binding to amyloid deposits from multiple amyloidogenic proteins.

AUTHORS: Olivier F. Clerc, Sarah A.M. Cuddy, Matthew Robertson, Shilpa Vijayakumar, Jocelyn Canseco Neri, Vaidehi Chemburkar, Marie Foley Kijewski, Marcelo F. Di Carli, Giada Bianchi, Rodney H. Falk, Sharmila Dorbala

Trasis and Sysark join forces to develop and distribute an automated dispenser for radiopharmaceuticals

Trasis announces its new partnership as exclusive distributor of innovative solutions from the French company Sysark. This collaboration aims to offer a significant advance in the preparation and management of radiopharmaceutical drugs, with a focus on the world’s first automated device dedicated to the preparation, mixing, storage and sampling of Tc99m radiopharmaceuticals.